Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib long-term extension in ulcerative colitis
NCT03006068Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2017
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 46
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in ulcerative colitis (UC) (5 arms), sponsored by AbbVie Inc. Primary endpoint: Treatment-Emergent Adverse Events at 288 weeks. Started Jan 2017; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03006068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006068.